Minerva Neurosciences, Inc. (NERV)

Minerva Neurosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	34.92	41.01	36.19	60.86	25.46	21.51
Short-Term Investments	0	0	0	0	0	24.44
Cash & Cash Equivalents	34.92	41.01	36.19	60.86	25.46	45.95
Cash Growth	-3.21%	13.31%	-40.52%	139.05%	-44.60%	-47.84%
Other Current Assets	0.7	0.99	3.97	1.35	1.98	1.18
Total Current Assets	35.62	42	40.16	62.2	27.44	47.14
Property, Plant & Equipment	0.01	0.01	0.02	0	0.1	0.28
Goodwill and Intangibles	14.88	14.89	14.91	14.92	14.87	14.87
Other Long-Term Assets	0	0	0	0	15.21	15.21
Total Long-Term Assets	14.89	14.9	14.93	14.92	30.19	30.36
Total Assets	50.51	56.9	55.09	77.12	57.63	77.5
Accounts Payable	1.44	1.81	0.97	1.85	1	2.32
Deferred Revenue	0	0	0	0	0	41.18
Current Debt	0	0	0	0	0.11	0.17
Other Current Liabilities	1.4	1.54	0.41	0.97	2.05	-37.04
Total Current Liabilities	2.83	3.34	1.38	2.82	3.16	6.63
Long-Term Debt	0	0	0	0	0	0.11
Other Long-Term Liabilities	84.27	82.02	73.73	66.33	1.8	42.98
Total Long-Term Liabilities	84.27	82.02	73.73	66.33	1.8	43.09
Total Liabilities	87.1	85.36	75.11	69.15	4.96	49.72
Total Debt	0	0	0	0	0.11	0.28
Debt Growth	-	-	-	-	-60.85%	-
Retained Earnings	-405.38	-396.82	-366.81	-334.7	-284.8	-286.74
Shareholders' Equity	-36.59	-28.46	-20.02	7.98	52.66	27.78
Net Cash / Debt	34.92	41.01	36.19	60.86	25.35	45.67
Net Cash / Debt Growth	-3.21%	13.31%	-40.52%	140.10%	-44.50%	-48.16%
Net Cash Per Share	4.61	6.30	6.78	11.40	4.96	9.36
Working Capital	32.79	38.66	38.78	59.38	24.28	40.51
Book Value Per Share	-4.83	-4.37	-3.75	1.49	10.32	5.70

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).